Dermatologists, surgeons, oncologists and radiotherapists usually jointly manage skin cancers. The strengths and limitations of the established procedures are known. A new naturally derived topical cream, Curaderm BEC5 , for the treatment of non melanoma skin cancers has previously been described. In this communication, intra-comparison treatments of skin cancer between Curaderm BEC5 therapy and the established treatments, surgery, radiation therapy, laser therapy, photodynamic therapy, imiquimod cream and cryosurgery are presented. Non melanoma skin cancer cases that had previously been treated unsuccessfully with the established procedures were subsequently treated successfully with Curaderm BEC5 . These observations are interesting because the identical lesions were treated by various modalities. In addition to the superior efficacious outcome of Curaderm BEC5 therapy versus the established treatments, the cosmetic end results with Curaderm BEC5 treatment are remarkable.
Most sick people go to any lengths to get better. To date, this translates to the sick person engaging a healthcare professional resulting in dependency of the patient on the healthcare professional. In turn, the healthcare professional relies and depends on medical information for the particular disease, which is obtained from pharmaceutical companies.
Herewith lies the dilemma. The healthcare professional has the wellbeing of the patient at heart, but due to his/her medical training with pharmaceuticals, the healthcare professional is largely dependent on information from the pharmaceutical industry.
Other than questionable efficacy of some medications, the fact remains that the cost of innovative, patent protected drugs from pharmaceutical companies is becoming increasingly difficult for patients and cash-strapped healthcare systems [
Regarding the disease cancer, the pharmaceutical industry has little to offer, as proven by the overall very limited successes, achieved by “established” procedures.
It is only after the established drugs and/or other established treatment regimes fail, which in the case of cancer, is often inevitable, the patient is faced with seeking other possible treatments. At this stage the disease would have progressed to a possible life threatening path and the valuable time for recovery is lost. Furthermore, the current established treatments for cancer are expensive, very toxic to the body and complicate any further alternative therapy.
It can be argued that the established therapies for cancer have had a fair go, and unfortunately, are suboptimal and are reaching a dead end despite of the further research and development.
It is also interesting to note that when the pharmaceutical industry develops a drug, either synthetic or natural, it is branded as an “established conventional” drug. If that same drug is developed by a small institution, using the same development procedures as the large pharmaceutical companies, the drug is branded as an “alternative” drug that exists outside the established society.
The time is now overdue to try “proven” safe alternatives for the treatment of cancer. The natural approach to treat cancer should be given an opportunity to be the first, not the last method of treatment in order for the patient to have a reasonable chance to overcome the medical condition without prior induced toxicity. Critical evaluation of the alternative treatments will determine whether this approach will produce an acceptable therapy or not.
To show the potential of this concept, clinical cases of skin cancers comparing accepted “established” treatment procedures as opposed to a novel naturally derived topical “alternative” treatment are presented.
CuradermBEC5 cream for topical application contains the established antineoplastic agents solasodine rhamnosides which are composed of solamargine and solasonine. Specific endogenous endocytic lectins (EELs) have been identified on cancer cells [
This communication describes the results of intra-comparison treatments, of the same non melanoma skin cancers, by established procedures compared with a treatment using CuradermBEC5, a topical cream formulation containing naturally derived solasodine rhamnosides.
The non melanoma skin cancer cases presented in this communication are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
BCC is a nonmelanocytic skin cancer that arises from basal cells which are small round cells found in the lower layer of the epidermis. BCC is the most common skin cancer in humans. BCC typically appears on sun- exposed skin, and is slow growing and rarely metastasize. BCC usually appears as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, waxy and the area may bleed following minor injury. Tumor size can vary from a few millimeters to several centimeters in diameter. BCC is diagnosed with a skin biopsy.
Cutaneous squamous cell carcinoma (c SCC) is the second most common human cancer. c SCC typically manifests as a spectrum of progressively advanced malignancies, ranging from a precursor actinic keratosis (AK) to SCC in situ (SCC is), invasive c SCC, and finally metastatic SCC.
Like BCC, SCC is associated with sun damage. Unlike BCC, SCC can metastasize and is potentially deadly. The classic presentation of a c SCC is that of a shallow ulcer with heaped-up edges, often covered by a plaque. Typical surface changes may include, scaling, ulceration, crusting or a cutaneous horn. Like BCC, c SCC can vary in size from a few millimeters to several centimeters in diameter. SCC is also diagnosed with a skin biopsy.
Unbiased selection of study population: only patients with confirmed histological diagnoses were selected. Two patients with c SCC and 4 patients with BCC were treated by the various procedures.
Procedures used to treat the patients:
Surgical Excision
The skin cancer was surgically excised by a surgeon followed by skin grafting [
Radiation Therapy
Radiation therapy uses high-energy rays (X-rays) or particles (photons, electrons or protons) to kill cancer cells [
Laser Therapy
Laser therapy uses an intense, focused beam of light to destroy skin cancer tissue [
Photodynamic Therapy (PDT)
PDT uses special drugs, called photosensitizing agents, along with light to kill cancer cells [
Imiquimod Cream
Imiquimod cream works by modifying the immune response to treat superficial skin cancers [
Cryosurgery
Cryosurgery (also called cryotherapy) is the use of extreme cold produced by liquid nitrogen (or argon gas) to destroy abnormal tissue. Cryosurgery is used to treat external tumours, such as those on the skin [
CuradermBEC5 Cream
This cream is available to patients in several countries. CuradermBEC5 cream contains antineoplastic solasodine rhamnosides (BEC), which are extracted from the fruit of Solanum linnaeanum [
All procedures were performed by specialists (dermatologists, surgeons and oncologists). The topical applications with the cream formulations were adhered to according to their treatment instructions [
None of the photographs were adulterated.
All treatment procedures applied to the patients are clinically available and no Approval by the Ethics Committee was necessary.
CuradermBEC5 versus surgical excision (Patient 1)
A 55-year-old male had an SCC, for over a year, on his head.
CuradermBEC5 versus radiation therapy (Patient 2)
CuradermBEC5 versus laser therapy (Patient 3)
A 24-year-old female patient was treated with laser therapy for a BCC close to the right eye. The BCC recurred after laser therapy (
sponded rapidly toward CuradermBEC5 treatment.
CuradermBEC5 versus photodynamic therapy (Patient 4)
CuradermBEC5 versus cryosurgery (Patient 5)
This male patient had previously undergone cryosurgery for a BCC on the right temporal region.
CuradermBEC5 versus imiquimod cream (Patient 6)
This patient had treated Bowen’s Disease (SCC in situ) on the penis for over 2 years with 5% Imiquimod cream; response appeared initially satisfactory, but the lesion was still present after 2 courses of Imiquimod treatments. Subsequently, the patient elected to treat his Bowen’s Disease with CuradermBEC5.
clinical improvement was observed after 4 months (
Overall observations with CuradermBEC5 therapy
During CuradermBEC5 therapy, initially, the lesions appear to become larger, but this is only transient. Continuous treatments result in diminishing of the size of the tumor until the tumor is completely ablated and is replaced with normal tissue. During treatment with CuradermBEC5 the cancer cells are killed and replaced with normal cells, CuradermBEC5 does not kill normal cells. In the initial stages of CuradermBEC5 therapy some patients experience local irritation, even a burning sensation, for several minutes after application of the cream to the lesion, but again, this is transient. Depending on the size of the tumor, some ulceration does occur. Follow- up with all of the patients for at least one year after CuradermBEC5 treatment showed no recurrences of the treated lesions.
To compare different modality treatments of a disease, large numbers of patients are required to establish possible statistical significant differences. Even so, the inter variability of the disease makes it more scientifically acceptable to conduct cross-over clinical trials which are only applicable with certain diseases. In the case of treating skin cancer this approach is not possible.
One way to compare the efficacy of treatment procedures is by performing an intra patient disease approach. This approach has been applied with the current studies and can be considered as preliminary only. Nevertheless, it is quite clear that CuradermBEC5 therapy is at least equally effective or more effective than other well ‘established’ treatment modalities.
The reported skin cancer patients in this communication were not cherry-picked. All patients, except the patient represented in
These patients presented an opportunity to compare and contrast the various treatment procedures on identical lesions in terms of safety, efficacy, ease of treatment, cosmetic outcomes and costs of treatment.
This report identifies that, due to specificity, the efficacy of CuradermBEC5 is superior compared to the other procedures. To the best of our knowledge, at this stage, we are unaware of cases where CuradermBEC5 therapy has failed and other treatments have been successful for treating the same lesions.
Most of the other described procedures are much more complicated and costly compared with CuradermBEC5 therapy. It is also beneficial that CuradermBEC5 therapy does not require continuous physician or hospital attendance.
The cosmetic outcomes with CuradermBEC5 therapy are far superior and confirm previous studies [
The need for a new treatment of skin cancer is warranted. Skin cancer is the most common form of human cancer. Over the past three decades, more people have had skin cancer than all other cancers combined. BCC is the most common form of skin cancer, an estimated 2.8 million BCCs are diagnosed annually in the USA. BCCs are rarely fatal, but can be highly disfiguring if allowed to grow. Over three thousand deaths from advanced BCCs occur annually in the USA [
This article describes the superiority of CuradermBEC5 therapy compared with other widely used modalities, both in efficacy and cosmesis, on the most prevalent skin cancers, BCCs and SCCs.
CuradermBEC5 offers an exceptional safe treatment that selectively eliminates skin cancer without disturbing the healing process.
Finally, this communication exemplifies that ‘alternative’ natural treatments should be seriously considered for a wide range of diseases with appropriate stringent evaluation. It is interesting to note that currently, approximately 50% of patients who had previously used laser, surgery or cryotherapy for their skin cancers now prefer CuradermBEC5 (personal communication, Institute of Clinical Oncology, Russian Cancer Research Centre).
Patients included in this study presented exceptional circumstances whereby direct treatment comparisons of identical BCCs and SCCs could be assessed by various widely used skin cancer therapies and CuradermBEC5 topical therapy.
The relative merits of CuradermBEC5 therapy over the described other established modalities are specificity, superior efficacy, superior cosmesis, low toxicity, non continuous physician or hospital attendance and low cost.
Skin cancer is by far the most common form of human cancer and the incidence of skin cancer is increasing. It is fortunate that a simple but very effective and safe therapy for skin cancer is now available. For the benefit of the patient, CuradermBEC5 is the therapy that should be considered as the method of choice for treating non melanoma skin cancers. Finally, here it is shown that not all-outstanding therapeutics comes from multi-billion pharmaceutical companies.
The following Dermatologists and Oncologists supervised the treatments of the patients: Dr. R. Theile―Patient 1,
K.Cham,A.Cham,T.Chase,V.Zhou,B.Cham, (2015) Treatment of Non Melanoma Skin Cancers: An Intra-Comparison Study of CuradermBEC5 and Various Established Modalities. Journal of Cancer Therapy,06,1045-1053. doi: 10.4236/jct.2015.612114
AK: actinic keratosis
Bax, Bcl-2, Bcl-x: apoptotic regulatory proteins
BCC: basal cell carcinoma
BEC: a specific mixture of solasodine rhamnosides
Caspase-8, -9, -3: a group of intracellular proteases responsible for the disassembly of the cell into apoptotic bodies
c SCC: cutaneous squamous cell carcinoma
EEL: endogenous endocytic lectin
Fas: a protein member of tumor necrosis factor receptor superfamily
PDT: photodynamic therapy
RBP: rhamnose binding protein
SCC: squamous cell carcinoma
SCC is: squamous cell carcinoma in situ
TNF-1: tumor necrosis factor receptor